CERo Therapeutics Holdings, Inc.
CEROW
Other OTC0.00
USD
+0.00
- -
CERo Therapeutics Holdings, Inc.
CEROW
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CERo Therapeutics Holdings, Inc. is an immunotherapy company focused on the development of engineered T cell therapeutics for cancer treatment. Its core products include Chimeric Engulfment Receptor T cells (CER-T), a novel cellular immunotherapy platform designed to integrate characteristics of both innate and adaptive immunity into single T cells. The company's lead product candidate, CER-1236, is an autologous T-cell therapy targeting a novel tumor antigen TIM-4 ligand, with clinical applications aimed at hematological malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CERo's proprietary technology aims to redirect patient-derived T cells to eliminate tumors by employing phagocytic mechanisms that uniquely combine engulfment pathways for tumor clearance, setting it apart from conventional CAR-T therapies. The company operates primarily in the United States, with headquarters in Oakland, California, and targets both liquid and solid tumors through its pipeline development. Recent major developments include the completion of the first cohort in its Phase 1/1b clinical trial of CER-1236 in AML, demonstrating in-vivo cell expansion and no dose-limiting toxicities, with regulatory approval obtained for dose intensification in the ongoing trial. CERo has completed a Series E financing round raising approximately $7 million, along with additional subscriptions, to extend its cash runway and support Nasdaq compliance, aiming at Nasdaq listing and up-listing options to improve liquidity and market accessibility. The company also finalized a business combination with Phoenix Biotech Acquisition Corp. in early 2024, enabling it to trade on Nasdaq under the ticker CERO. Further clinical trial activations are underway, including site activation at MD Anderson Cancer Center, supported by recent FDA IND allowances for CER-1236 in liquid and solid tumors. CERo continues to advance its portfolio with plans for expanding clinical trials and developing next-generation engineered T cell therapeutics incorporating multi-mechanism tumor clearance strategies. Founded in 2021, CERo Therapeutics is positioning itself at the forefront of cancer immunotherapy innovation, leveraging its dual-mode T cell engineering platform to address difficult-to-treat cancers with the goal of pioneering curative cell therapies. Its operations include ongoing clinical development, investor funded expansions, and strategic initiatives to transition toward more accessible public trading platforms while maintaining a strong focus on research and development within hematologic malignancies and solid tumor indications.